Sepul Bio Doses First Patient in Phase 2b Trial of Ultevursen for USH2A-Associated Retinitis Pigmentosa
Sepul Bio has announced the dosing of the first patient in the LUNA clinical study, a Phase 2b trial evaluating ultevursen for the treatment of USH2A-associated retinitis pigmentosa (RP). This milestone represents renewed hope for individuals affected by …